Travere Therapeutics announced the FDA granted accelerated approval to Filspari, also known as sparsentan, according to a company press release.
Filspari is a once-daily oral medication designed to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. The medication is the first and only non-immunosuppressive therapy approved for this condition.
“The accelerated approval of [Filspari] is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community,” Eric Dube, PhD, president and chief
FDA grants accelerated approval to Filspari for reduced proteinuria in IgA nephropathy
Travere Therapeutics announced the FDA granted accelerated approval to Filspari, also known as sparsentan, according to a company press release.
Filspari is a once-daily oral medication designed to reduce proteinuria in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. The medication is the first and only non-immunosuppressive therapy approved for this condition.
“The accelerated approval of [Filspari] is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community,” Eric Dube, PhD, president and chief